000 05945nam a22005055i 4500
001 978-3-031-38605-3
003 DE-He213
005 20240729135736.0
007 cr nn 008mamaa
008 240229s2023 sz | s |||| 0|eng d
020 _a9783031386053
_9978-3-031-38605-3
024 7 _a10.1007/978-3-031-38605-3
_2doi
072 7 _aMJCL
_2bicssc
072 7 _aMED062000
_2bisacsh
072 7 _aMJCL
_2thema
245 1 0 _aPractical Management of Thyroid Cancer
_b : A Multidisciplinary Approach /
250 _a3rd ed. 2023.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2023.
300 _aXVI, 399 p. 45 illus., 31 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _a1. Pragmatism, Precision Oncology, International Partnership for Research and Quality-The New Paradigm for Thyroid Cancer -- Section I. Multidisciplinary Approach to Management of Thyroid Cancer -- 2. The UK Evidence-Based Guidelines for the Management of Thyroid Cancer: Key Recommendations -- 3. The 2015 American Thyroid Association Evidence-Based Guidelines for Management of Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Key Recommendations -- 4. Thyroid Cancer: One Doctor-Patient Partnership -The Newcastle Butterfly Model -- Section II. The Diagnosis of Thyroid Cancer -- 5. Molecular Diagnosis of Thyroid Nodules -- 6. Ultrasonography in Diagnosis and Management of Thyroid Cancer -Current International Recommendations -- Section III. Initial Thyroid Surgery -- 7. The 21st Century Endocrine Surgeon -- 8. Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer -- 9. Advances in Thyroid Surgery -- Section IV. Non surgical Management ofDifferentiated Thyroid Cancer -- 10. Risk Stratification and Current Management of Low Risk Thyroid Cancer -- 11. Management of Low risk Papillary Thyroid Carcinomo and Papillary Cancer and Microcarcinoma-the Japanese experience -- 12. Radioiodine Ablation - Current Status -- 13. Dosimetric Approaches - Current Concepts -- 14. External Radiation in Differentiated Thyroid Cancer in the era of IMRT and modern radiation planning techniques -- Section V. Follow up and Longterm Management of Differentiated Thyroid Cancer -- 15. Thyroglobulin -- 16. Management of Post-Operative Hypocalcemia -- 17. Radioiodine Refractory Thyroid Cancer -- Section VI. Medullary Thyroid Carcinoma -- 18. Medullary Thyroid Cancer :Surgical Management -- 19. Medullary Thyroid Cancer: Diagnosis and Non Surgical Management -- 20. Familial Non-Medullary Thyroid Cancer -- Section VII. Thyroid Cancer in Children -- 21. Pediatric Differentiated Thyroid Carcinoma -- Section VIII. Aggressive ThyroidCancers -- 22. Anaplastic Thyroid Cancer -- 23. Palliative care -- Section IX. Future Developments and Directions for Research in Thyroid Cancer -- 24. Translational Research and Genomics Driven Trials in Thyroid Cancer -- 25. Thyroid Cancer Trials -- 26. The Barriers to Uniform Implementation of Clinical Practice Guidelines (CPG) for Thyroid Cancer -- 27. Survivorship: The Role of the Clinical Psychologist and the Clinical Nurse Specialist in Thyroid Cancer Care.
520 _aWritten by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer. It provides a global health perspective, striving towards a uniform, equitable, evidence-based, cost-effective, practical, and patient-centred approach with high quality care crossing geographical boundaries. This book covers controversial issues and the most up-to-date management of differentiated, medullary, anaplastic, and rarer types of thyroid cancers together with survivorship issues and the lessons learnt during the Covid-19 Pandemic. The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRK gene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed. The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well. This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.
650 0 _aOncology.
_913364
650 0 _aSurgery.
650 0 _aEndocrinology.
_96049
650 0 _aPrimary care (Medicine).
650 0 _aPathology.
650 1 4 _aOncology.
_913364
650 2 4 _aSurgery.
650 2 4 _aEndocrinology.
_96049
650 2 4 _aPrimary Care Medicine.
650 2 4 _aPathology.
700 1 _aMallick, Ujjal K.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aHarmer, Clive.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
856 _u#gotoholdings
_yAccess resource
912 _aZDB-2-SME
912 _aZDB-2-SXM
245 _h[E-Book]
999 _c103205
_d103205